Indian Journal of Pharmacology Home 

DRUG WATCH
[View FULLTEXT] [Download PDF]
Year : 2013  |  Volume : 45  |  Issue : 2  |  Page : 195--196

Aripiprazole monotherapy in an adolescent worsens psychosis

Mahima Panigrahi1, Susanta Kumar Padhy2, Rajesh Rathi3 
1 Department of Preventive and Social Medicine, Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha, India
2 Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Psychiatry, Jawaharlal Nehru Medical College, Sawangi Meghe, Wardha, Maharastra, India

Correspondence Address:
Susanta Kumar Padhy
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh
India

Early detection and treatment of early onset schizophrenia (EOS) can lead to better outcome. Aripiprazole, a partial agonist of dopamine and a second generation antipsychotic, has been approved specifically for treatment of children with schizophrenia of aged 13-17 years. Though the use of this drug in adults may be associated with worsening of psychosis in occasional cases, no such data is available in adolescents. We report a case of EOS, who had worsening of psychosis with aripiprazole monotherapy. We discuss the possible mechanisms and clinical implications relevant in adolescents, and alert the clinicians to be vigilant in monitoring the patients on aripiprazole, especially after an increase in the dose of this medication.


How to cite this article:
Panigrahi M, Padhy SK, Rathi R. Aripiprazole monotherapy in an adolescent worsens psychosis.Indian J Pharmacol 2013;45:195-196


How to cite this URL:
Panigrahi M, Padhy SK, Rathi R. Aripiprazole monotherapy in an adolescent worsens psychosis. Indian J Pharmacol [serial online] 2013 [cited 2022 Aug 10 ];45:195-196
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2013;volume=45;issue=2;spage=195;epage=196;aulast=Panigrahi;type=0